ccr5 ccr5 c-c chemokine receptor type 5, also known as ccr5 or cd195, is a protein on the surface of white blood cells that is involved in the immune system as it acts as a receptor for chemokines. ccr5available structurespdbortholog search: pdbe rcsb list of pdb id codes2l87, 2rll, 2rrs, 2mzx, 4mbsidentifiersaliasesccr5, cc-ckr-5, ccckr5, ccr-5, cd195, ckr-5, ckr5, cmkbr5, iddm22, c-c motif chemokine receptor 5 (gene/pseudogene), c-c motif chemokine receptor 5external idsomim: 601373 mgi: 107182 homologene: 37325 genecards: ccr5 gene location (human)chr.chromosome 3 (human)band3p21.31start46,370,946 bpend46,376,206 bpgene location (mouse)chr.chromosome 9 (mouse)band9 f4|9 75.05 cmstart123,921,580 bpend123,947,736 bprna expression patternbgeehumanmouse (ortholog)top expressed inparietal pleuravisceral pleurapalpebral conjunctivagerminal epitheliummucosa of urinary bladderappendixsuperficial temporal arteryjejunal mucosalymph nodemonocytetop expressed inmorulabloodlymph nodesubmandibular glandsuperior frontal gyrusspleenblastocystthymusuteruswhite adipose tissuemore reference expression databiogpsn/agene ontologymolecular function g protein-coupled receptor activity coreceptor activity chemokine (c-c motif) ligand 5 binding virus receptor activity signal transducer activity protein binding chemokine receptor activity c-c chemokine receptor activity actin binding phosphatidylinositol phospholipase c activity c-c chemokine binding chemokine binding cellular component cytoplasm integral component of membrane endosome membrane plasma membrane integral component of plasma membrane external side of plasma membrane cell surface biological process g protein-coupled receptor signaling pathway signaling response to cholesterol release of sequestered calcium ion into cytosol by sarcoplasmic reticulum positive regulation of cytosolic calcium ion concentration cell-cell signaling dendritic cell chemotaxis mapk cascade chemotaxis cellular defense response cell surface receptor signaling pathway immune response inflammatory response cellular response to lipopolysaccharide calcium ion transport calcium-mediated signaling signal transduction fusion of virus membrane with host plasma membrane chemokine-mediated signaling pathway viral process defense response negative regulation of macrophage apoptotic process cytokine-mediated signaling pathway cell chemotaxis sources:amigo / quickgoorthologsspecieshumanmouseentrez123412774ensemblensg00000160791ensmusg00000079227uniprotp51681p51682refseq (mrna)nm_001100168nm_000579nm_001394783nm_009917refseq (protein)np_000570np_001093638np_034047location (ucsc)chr 3: 46.37 – 46.38 mbchr 9: 123.92 – 123.95 mbpubmed searchwikidataview/edit humanview/edit mouse attachment of hiv to a cd4+ t-helper cell: 1) the gp120 viral protein attaches to cd4. 2) gp120 variable loop attaches to a coreceptor, either ccr5 or cxcr4. 3) hiv enters the cell. in humans, the ccr5 gene that encodes the ccr5 protein is located on the short (p) arm at position 21 on chromosome 3. certain populations have inherited the delta 32 mutation, resulting in the genetic deletion of a portion of the ccr5 gene. homozygous carriers of this mutation are resistant to m-tropic strains of hiv-1 infection. function the ccr5 protein belongs to the beta chemokine receptors family of integral membrane proteins. it is a g protein–coupled receptor which functions as a chemokine receptor in the cc chemokine group. ccr5's cognate ligands include ccl3, ccl4 (also known as mip 1α and 1β, respectively), and ccl3l1. ccr5 furthermore interacts with ccl5 (a chemotactic cytokine protein also known as rantes). ccr5 is predominantly expressed on t cells, macrophages, dendritic cells, eosinophils, microglia and a subpopulation of either breast or prostate cancer cells. the expression of ccr5 is selectively induced during the cancer transformation process and is not expressed in normal breast or prostate epithelial cells. approximately 50% of human breast cancer expressed ccr5, primarily in triple negative breast cancer. ccr5 inhibitors blocked the migration and metastasis of breast and prostate cancer cells that expressed ccr5, suggesting that ccr5 may function as a new therapeutic target. recent studies suggest that ccr5 is expressed in a subset of cancer cells with characteristics of cancer stem cells, which are known to drive therapy resistance, and that ccr5 inhibitors enhanced the number of cells killed by current chemotherapy. it is likely that ccr5 plays a role in inflammatory responses to infection, though its exact role in normal immune function is unclear. regions of this protein are also crucial for chemokine ligand binding, the functional response of the receptor, and hiv co-receptor activity. modulation of ccr5 activity contributes to a non-pathogenic course of infection with simian immunodeficiency virus (siv) in several african non-human primate species that are long-term natural hosts of siv and avoid immunodeficiency upon the infection. these regulatory mechanisms include: genetic deletions that abrogate cell surface expression of ccr5, downregulation of ccr5 on the surface of cd4+ t cells, in particular on memory cells, and delayed onset of ccr5 expression on the cd4+ t cells during development. primary protein sequence hiv further information: hiv tropism and entry inhibitor hiv-1 most commonly uses the chemokine receptors ccr5 and/or cxcr4 as co-receptors to enter target immunological cells. these receptors are located on the surface of host immune cells whereby they provide a method of entry for the hiv-1 virus to infect the cell. the hiv-1 envelope glycoprotein structure is essential in enabling the viral entry of hiv-1 into a target host cell. the envelope glycoprotein structure consists of two protein subunits cleaved from a gp160 protein precursor encoded for by the hiv-1 env gene: the gp120 external subunit and the gp41 transmembrane subunit. this envelope glycoprotein structure is arranged into a spike-like structure located on the surface of the virion and consists of a trimer of gp120-gp41 hetero-dimers. the gp120 envelope protein is a chemokine mimic. though it lacks the unique structure of a chemokine, it is still capable of binding to the ccr5 and cxcr4 chemokine receptors. during hiv-1 infection, the gp120 envelope glycoprotein subunit binds to a cd4 glycoprotein and a hiv-1 co-receptor expressed on a target cell, forming a heterotrimeric complex. the formation of this complex stimulates the release of a fusogenic peptide, causing the viral membrane to fuse with the membrane of the target host cell. because binding to cd4 alone can sometimes result in gp120 shedding, gp120 must next bind to co-receptor ccr5 in order for fusion to proceed. the tyrosine-sulfated amino terminus of this co-receptor is the "essential determinant" of binding to the gp120 glycoprotein. the co-receptor also recognizes the v1-v2 region of gp120 and the bridging sheet (an antiparallel, 4-stranded β sheet that connects the inner and outer domains of gp120). the v1-v2 stem can influence "co-receptor usage through its peptide composition as well as by the degree of n-linked glycosylation." unlike v1-v2 however, the v3 loop is highly variable and thus is the most important determinant of co-receptor specificity. the normal ligands for this receptor, rantes, mip-1β, and mip-1α, are able to suppress hiv-1 infection in vitro. in individuals infected with hiv, ccr5-using viruses are the predominant species isolated during the early stages of viral infection, suggesting that these viruses may have a selective advantage during transmission or the acute phase of disease. moreover, at least half of all infected individuals harbor only ccr5-using viruses throughout the course of infection. ccr5 is the primary co-receptor used by gp120 sequentially with cd4. this bind results in gp41, the other protein product of gp160, released from its metastable conformation and inserted into the membrane of the host cell. although it has not been confirmed, binding of gp120-ccr5 involves two crucial steps: 1) the tyrosine-sulfated amino terminus of this co-receptor is an "essential determinant" of binding to gp120 (as stated previously) 2) following step 1., there must be reciprocal action (synergy, intercommunication) between gp120 and the ccr5 transmembrane domains. ccr5 is essential for the spread of the r5-strain of the hiv-1 virus. knowledge of the mechanism by which this strain of hiv-1 mediates infection has prompted research into the development of therapeutic interventions to block ccr5 function. a number of new experimental hiv drugs, called ccr5 receptor antagonists, have been designed to interfere with binding between the gp120 envelope protein and the hiv co-receptor ccr5. these experimental drugs include pro140 (cytodyn), vicriviroc (phase iii trials were cancelled in july 2010) (schering plough), aplaviroc (gw-873140) (glaxosmithkline) and maraviroc (uk-427857) (pfizer). maraviroc was approved for use by the fda in august 2007. it is the only one thus far approved by the fda for clinical use, thus becoming the first ccr5 inhibitor. a problem of this approach is that, while ccr5 is the major co-receptor by which hiv infects cells, it is not the only such co-receptor. it is possible that under selective pressure hiv will evolve to use another co-receptor. however, examination of viral resistance to ad101, molecular antagonist of ccr5, indicated that resistant viruses did not switch to another co-receptor (cxcr4), but persisted in using ccr5: they either bound to alternative domains of ccr5 or to the receptor at a higher affinity. however, because there is still another co-receptor available, it is probable that lacking the ccr5 gene does not make one immune to the virus; it would simply be more challenging for the individual to contract it. also, the virus still has access to cd4. unlike ccr5, which is not required (as evidenced by those living healthy lives even when lacking the gene as a result of the delta32 mutation), cd4 is critical in the body's immune defense system. even without the availability of either co-receptor (even ccr5), the virus can still invade cells if gp41 were to go through an alteration (including its cytoplasmic tail) that resulted in the independence of cd4 without the need of ccr5 and/or cxcr4 as a doorway. cancer expression of ccr5 is induced in breast and prostate epithelial cells upon transformation. the induction of ccr5 expression promotes cellular invasion, migration, and metastasis. the induction of metastasis involves homing to the metastatic site. ccr5 inhibitors including maraviroc and leronlimab have been shown to block lung metastasis of human breast cancer cell lines. in preclinical studies of immune competent mice ccr5 inhibitors blocked metastasis to the bones and brain. ccr5 inhibitors also reduce the infiltration of tumor associated macrophages. a phase 1 clinical study of a ccr5 inhibitor in heavily pretreated patients with metastatic colon cancer demonstrated an objective clinical response and reduction in metastatic tumor burden. brain increased levels of ccr5 are part of the inflammatory response to stroke and death. blocking ccr5 with maraviroc (a drug approved for hiv) may enhance recovery after stroke. in the developing brain, chemokine receptors such as ccr5 influence neuronal migration and connection. after stroke, they seem to decrease the number of connection sites on neurons near the damage. ccr5-δ32 ccr5-δ32 (or ccr5-d32 or ccr5 delta 32) is an allele of ccr5. ccr5 δ32 is a 32-base-pair deletion that introduces a premature stop codon into the ccr5 receptor locus, resulting in a nonfunctional receptor. ccr5 is required for m-tropic hiv-1 virus entry. individuals homozygous (denoted δ32/δ32) for ccr5 δ32 do not express functional ccr5 receptors on their cell surfaces and are resistant to hiv-1 infection, despite multiple high-risk exposures. individuals heterozygous (+/δ32) for the mutant allele have a greater than 50% reduction in functional ccr5 receptors on their cell surfaces due to dimerization between mutant and wild-type receptors that interferes with transport of ccr5 to the cell surface. heterozygote carriers are resistant to hiv-1 infection relative to wild types and when infected, heterozygotes exhibit reduced viral loads and a 2-3-year-slower progression to aids relative to wild types. heterozygosity for this mutant allele also has shown to improve one's virological response to anti-retroviral treatment. ccr5 δ32 has an (heterozygote) allele frequency of 9% in europe, and a homozygote frequency of 1%. recent research indicates that ccr5 δ32 enhances cognition and memory. in 2016, researchers showed that removing the ccr5 gene from mice significantly improved their memory. ccr5 is a powerful suppressor for neuronal plasticity, learning, and memory; ccr5 over-activation by viral proteins may contribute to hiv-associated cognitive deficits. evolutionary history and age of the allele the ccr5 δ32 allele is notable for its recent origin, unexpectedly high frequency, and distinct geographic distribution, which together suggest that (a) it arose from a single mutation, and (b) it was historically subject to positive selection. two studies have used linkage analysis to estimate the age of the ccr5 δ32 deletion, assuming that the amount of recombination and mutation observed on genomic regions surrounding the ccr5 δ32 deletion would be proportional to the age of the deletion. using a sample of 4000 individuals from 38 ethnic populations, stephens et al. estimated that the ccr5-δ32 deletion occurred 700 years ago (275-1875, 95% confidence interval). another group, libert et al. (1998), used microsatellite mutations to estimate the age of the ccr5 δ32 mutation to be 2100 years (700-4800, 95% confidence interval). on the basis of observed recombination events, they estimated the age of the mutation to be 2250 years (900-4700, 95% confidence interval). a third hypothesis relies on the north-to-south gradient of allele frequency in europe, which shows that the highest allele frequency occurred